DexCom Past Earnings Performance
Past criteria checks 5/6
DexCom has been growing earnings at an average annual rate of 24.2%, while the Medical Equipment industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 20.4% per year. DexCom's return on equity is 34.4%, and it has net margins of 17.2%.
Key information
24.2%
Earnings growth rate
23.5%
EPS growth rate
| Medical Equipment Industry Growth | 12.3% |
| Revenue growth rate | 20.4% |
| Return on equity | 34.4% |
| Net Margin | 17.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How DexCom makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,954 | 681 | 1,262 | 549 |
| 30 Jun 24 | 3,935 | 667 | 1,242 | 545 |
| 31 Mar 24 | 3,802 | 639 | 1,208 | 528 |
| 31 Dec 23 | 3,622 | 542 | 1,185 | 506 |
| 30 Sep 23 | 3,403 | 377 | 1,187 | 486 |
| 30 Jun 23 | 3,198 | 358 | 1,135 | 465 |
| 31 Mar 23 | 3,023 | 293 | 1,085 | 467 |
| 31 Dec 22 | 2,910 | 341 | 1,008 | 484 |
| 30 Sep 22 | 2,793 | 244 | 936 | 605 |
| 30 Jun 22 | 2,673 | 230 | 900 | 623 |
| 31 Mar 22 | 2,572 | 258 | 837 | 631 |
| 31 Dec 21 | 2,449 | 217 | 811 | 604 |
| 30 Sep 21 | 2,319 | 577 | 749 | 487 |
| 30 Jun 21 | 2,170 | 562 | 709 | 445 |
| 31 Mar 21 | 2,027 | 530 | 660 | 396 |
| 31 Dec 20 | 1,927 | 550 | 618 | 360 |
| 30 Sep 20 | 1,821 | 231 | 574 | 320 |
| 30 Jun 20 | 1,716 | 205 | 539 | 299 |
| 31 Mar 20 | 1,601 | 148 | 541 | 288 |
| 31 Dec 19 | 1,476 | 101 | 516 | 274 |
| 30 Sep 19 | 1,351 | -171 | 499 | 252 |
| 30 Jun 19 | 1,222 | -170 | 479 | 236 |
| 31 Mar 19 | 1,128 | -130 | 452 | 214 |
| 31 Dec 18 | 1,032 | -127 | 433 | 417 |
| 30 Sep 18 | 915 | 43 | 414 | 191 |
| 30 Jun 18 | 833 | -5 | 393 | 184 |
| 31 Mar 18 | 761 | -33 | 368 | 182 |
| 31 Dec 17 | 719 | -50 | 349 | 185 |
| 30 Sep 17 | 669 | -48 | 336 | 180 |
| 30 Jun 17 | 633 | -65 | 327 | 181 |
| 31 Mar 17 | 599 | -88 | 311 | 172 |
| 31 Dec 16 | 573 | -66 | 286 | 156 |
| 30 Sep 16 | 533 | -57 | 268 | 141 |
| 30 Jun 16 | 490 | -80 | 245 | 125 |
| 31 Mar 16 | 445 | -64 | 221 | 113 |
| 31 Dec 15 | 402 | -58 | 198 | 101 |
| 30 Sep 15 | 356 | -58 | 173 | 94 |
| 30 Jun 15 | 319 | -20 | 155 | 85 |
| 31 Mar 15 | 285 | -23 | 140 | 76 |
| 31 Dec 14 | 259 | -22 | 128 | 69 |
| 30 Sep 14 | 227 | -26 | 116 | 60 |
| 30 Jun 14 | 201 | -27 | 104 | 52 |
| 31 Mar 14 | 178 | -31 | 94 | 47 |
| 31 Dec 13 | 160 | -30 | 84 | 42 |
Quality Earnings: DXCM has high quality earnings.
Growing Profit Margin: DXCM's current net profit margins (17.2%) are higher than last year (11.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DXCM has become profitable over the past 5 years, growing earnings by 24.2% per year.
Accelerating Growth: DXCM's earnings growth over the past year (80.6%) exceeds its 5-year average (24.2% per year).
Earnings vs Industry: DXCM earnings growth over the past year (80.6%) exceeded the Medical Equipment industry 12.7%.
Return on Equity
High ROE: Whilst DXCM's Return on Equity (34.4%) is high, this metric is skewed due to their high level of debt.